Natera, Inc. (NASDAQ:NTRA) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its position in Natera, Inc. (NASDAQ:NTRA) by 7.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 636,851 shares of the medical research company’s stock after selling 52,843 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Natera were worth $80,848,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of NTRA. Itau Unibanco Holding S.A. acquired a new stake in Natera in the 2nd quarter valued at $28,000. Quarry LP boosted its position in shares of Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after buying an additional 190 shares during the period. GAMMA Investing LLC grew its stake in shares of Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after buying an additional 108 shares in the last quarter. Covestor Ltd raised its holdings in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after buying an additional 95 shares during the period. Finally, Brooklyn Investment Group acquired a new position in Natera during the 3rd quarter worth approximately $70,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Transactions at Natera

In related news, CEO Steven Leonard Chapman sold 5,024 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $128.48, for a total value of $645,483.52. Following the sale, the chief executive officer now owns 195,686 shares of the company’s stock, valued at $25,141,737.28. This trade represents a 2.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gail Boxer Marcus sold 2,212 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $158.53, for a total transaction of $350,668.36. Following the completion of the sale, the director now owns 19,386 shares in the company, valued at $3,073,262.58. The trade was a 10.24 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 46,503 shares of company stock worth $6,325,804. 7.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have recently issued reports on NTRA. UBS Group dropped their price objective on shares of Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. TD Cowen lifted their price target on shares of Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. The Goldman Sachs Group upped their price objective on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Finally, JPMorgan Chase & Co. boosted their price target on Natera from $135.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company. According to data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and a consensus price target of $140.59.

Natera Stock Up 1.2 %

NTRA stock opened at $169.82 on Tuesday. The firm has a fifty day moving average price of $136.43 and a two-hundred day moving average price of $120.84. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a 1-year low of $55.56 and a 1-year high of $171.95. The firm has a market cap of $22.42 billion, a price-to-earnings ratio of -96.49 and a beta of 1.53.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. During the same quarter in the prior year, the business earned ($0.95) earnings per share. Natera’s quarterly revenue was up 63.9% on a year-over-year basis. Research analysts predict that Natera, Inc. will post -1.66 EPS for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.